VALFIX Medical is an early-stage start-up company that creates minimally-invasive clinical devices with complete transcatheter repair solutions based on its multi-wire technology. The company's technology is designed to eliminate mitral regurgitation in over 90% of severe MR patients, providing a solution that is the closest to the surgical standard in transcatheter mitral valve repair and replacement. Currently, severe MR patients undergo open heart surgery, but only 2% of them receive this treatment, leaving the remaining 98% with drug therapy alone, resulting in nearly 50% of them dying within 2 years. VALFIX Medical aims to provide a viable alternative to open-heart valve surgery, alleviating heart failure symptoms and treating various medical heart-related conditions.